NOTE

🌱 created from: bite_rrmm

teclistamab

MajesTEC-1: pivotal, open-label, phase I/II trial of teclistamab in R/R MM

• Median time to first response: 1.2mo
• Median time to best response: 3.8mo
• Long-term
  • median follow-up:23mo